Leerink partnrs articles
-
Leerink Partnrs Reaffirms Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
Leerink Partnrs reiterated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a research report sent to investors on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Cartesian Therapeutics’ Q1 2024 earnings at ($1.34) EPS, Q2 2024 earnings at ($1.38) EPS, Q3 2024 earnings at ($1.27) EPS, Q4 2024 […]
-
Q1 2024 Earnings Forecast for LENZ Therapeutics, Inc. (NASDAQ:LENZ) Issued By Leerink Partnrs
LENZ Therapeutics, Inc. (NASDAQ:LENZ – Free Report) – Equities research analysts at Leerink Partnrs issued their Q1 2024 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a research report issued on Monday, April 15th. Leerink Partnrs analyst M. Goodman forecasts that the company will post earnings per share of ($0.51) for the